Introduction

Paclitaxel (Taxol
2
, Birstol-Myers Squibb, NJ, USA), an alkaloid originally isolated from the bark of the Paci®c yew tree (Taxus brevifolia), is an anti-cancer agent highly active against a variety of human cancers, including cancers of the breast, ovary, lung, colon and head and neck (Rowinsky, 1997) . The major intracellular target of paclitaxel is the cytoskeleton. Paclitaxel binds to polymerized tubulin and promotes assembly of microtubules, resulting in excessively stable mitotic spindles and disturbance of chromosome segregation at the metaphase (Horwitz, 1992; Schi and Horwitz, 1980) , and this subsequently leads to apoptosis (Sorger et al., 1997) . While induction of apoptosis by paclitaxel in tumor cells is well-documented (Amato et al., 1998; Blagosklonny et al., 1996; Horwitz, 1992; Lee et al., 1998; Wang et al., 1998) , the underlying mechanism by which paclitaxel induces cell death remains less understood. Previous studies have suggested involvement of the c-Jun N-terminal kinase (JNK)/stress-activated protein kinase (SAPK) activation during paclitaxelmediated apoptosis (Amato et al., 1998; Lee et al., 1998; Wang et al., 1998) . Paclitaxel has been shown to activate Raf-1 and to cause Bcl-2 phosphorylation (inactivation) at the G2/M phase concomitant with apoptosis (Blagosklonny et al., 1997; Haldar et al., 1996; Ling et al., 1998) . Expression of Bax in SW626 human ovarian cancer cells (Strobel et al., 1996) and of Bcl-X S in MCF7 human breast cancer cells (Sumantran et al., 1995) sensitized these cells to paclitaxel-mediated apoptosis. Conversely, expression of Bcl-X L in HL-60 human acute myeloid leukemia cells inhibited paclitaxel-mediated apoptosis (Ibrado et al., 1997) . Studies in the literature suggested that paclitaxel activated p34cdc2 kinase in MDA-MB-435 breast cancer cells, leading to cell cycle arrest at the G2/M phase and, subsequently, apoptosis (Yu et al., 1998) . Inhibition of p34cdc2 with speci®c synthetic compounds or expression of a p34cdc2 dominant-negative vector reduced paclitaxel-mediated apoptosis (Shen et al., 1998; Yu et al., 1998) . Reduction in the level of cyclin B by an antisense oligonucleotide also inhibited paclitaxel-mediated apoptosis (Shen et al., 1998) .
p34cdc2 kinase is a highly regulated serine/threonine kinase that, when complexed with cyclins A and B, controls cell entry into mitosis. Cells in mitosis often exhibit high levels of p34cdc2 activity (Verlhac et al., 1993) . Because paclitaxel targets microtubules, which play an important role in mitosis, we asked whether the increased activity of p34cdc2 upon paclitaxel treatment was a cause or a consequence of paclitaxelmediated apoptosis.
We also characterized the roles of p21 Waf1 and p27
Kip1
in regulating the cellular response to paclitaxel treatment. The CDK inhibitor p21 Waf1 has recently been demonstrated to arrest at G2 phase in addition to its inhibitory eect at G1 phase of cell cycle (Cayrol et al., 1998; Dulic et al., 1998; Medema et al., 1998; Niculescu et al., 1998) . In contrast, p27
Kip1 arrests cells only at G1 phase (Polyak et al., 1994; Toyoshima and Hunter, 1994) . We speculated that their impact on paclitaxel-mediated cytotoxicity might be dierent due to their dierential biological eects on cell cycle. We chose as a model for exploring paclitaxel-mediated apoptosis the human RKO colon adenocarcinoma cell line, and employed the ecdysone-inducible expression system to ectopically express p21
Waf1 or p27 Kip1 in these cells.
Our results indicate that the p21
Waf1
-expressing cells showed remarkably greater resistance to paclitaxelmediated apoptosis than did the p27 Kip1 -expressing cells. We further demonstrated that this dierence was attributed to the eects of p21
Waf1 on preventing cells from entering M phase of cell cycle, where they would become susceptible to paclitaxel-mediated cytotoxicity. In contrast, both p21 Waf1 and p27 Kip1 could inhibit paclitaxel-mediated elevation of p34cdc2 activity. Our observations argue against the role of p34cdc2 reported in literature, in which paclitaxel-activated p34cdc2 kinase was felt to be the cause of cell cycle arrest at G2/M phase and, subsequently, apoptosis (Shen et al., 1998; Yu et al., 1998) .
Results
Inducible expression of p21
Waf1 and p27 Kip1 in RKO cells
Several clones with inducible expression of p21 Waf1 or p27
Kip1 were obtained and produced comparable results. Figure 1a shows the time course induction of p21 Waf1 and p27
Kip1 in representative clones (named RKO-p21 and RKO-p27, respectively, hereafter) upon addition of the inducer (muristerone A) into the culture medium.
Induction of p21
Waf1 or p27 Kip1 was detectable approximately 2 h after addition, and expression peaked 24 h after addition of muristerone A. The increased levels of p21
Waf1 and p27 Kip1 persisted for at least 72 h without further supplementation with muristerone A. The ectopically expressed p21 Waf1 or p27 Kip1 was associated with CDK2 and CDK4, as shown by increased coimmunoprecipitation of CDK2 or CDK4 with antibodies directed against p21
Waf1 or p27 Kip1 (Figure 1b ). There was a less pronounced association of p21
Waf1 with CDK6 in comparison with the association of p27 Kip1 and CDK6 (Figure 1b, bottom panel) . Induction of p21
Waf1 or p27 Kip1 strongly inhibited CDK2 and CDK4 activity (Figure 1c) , however, no CDK6 kinase inhibition was observed in these cells upon induction of either p21
Waf1 or p27
Kip1
.
Expression of p21
Waf1 or p27 Kip1 was sucient to completely inhibit the proliferation of RKO cells (Figure 2a) . Flow cytometry analyses indicated that induction of p27
Kip1 for 24 h resulted in complete arrest of the cell cycle at G1 phase (Figure 2b ). In contrast, induction of p21
Waf1 arrested the cell cycle at two points, with the majority of cells in G1 phase and the rest in G2 phase. There was a higher percentage of cells in G2 phase at 48 h after p21
Waf1 induction (from 9 ± 26.8%). This higher proportion persisted at 72 h after p21
Waf1 induction (data not shown).
Differential effects of p21
Waf1 and p27 Kip1 on paclitaxel-mediated cytotoxicity
We hypothesized that the unique G2 block induced by p21
Waf1 might play a critical role in preventing RKOp21 cells from entering M phase, thereby rendering the cells less sensitive to treatments by M phase-interfering Waf1 and p27 Kip1 with cyclin-dependent kinases. RKO-p21 or RKO-p27 cells were cultured with or without 3 mM muristerone A for 24 h at 378C. p21
Waf1 and p27 Kip1 were immunoprecipitated from the lysates of non-induced (7) and induced cells (+). The immunoprecipitates were analysed by SDS ± PAGE and subsequently subjected to Western blot analysis for any co-precipitated CDKs with speci®c antibodies against CDK2, CDK4, and CDK6. (c) Inhibition of cyclin-dependent kinase activity by ectopically expressed p21 Waf1 and p27
Kip1
. RKO-p21 and RKO-p27 cells were incubated as described in (b). CDK2, CDK4, or CDK6 was immunoprecipitated from the lysates with corresponding speci®c antibodies. The immunoprecipitates were subjected to an Rb kinase assay Waf1 and p27 Kip1 . Cells were cultured for 24 or 48 h in culture medium in the absence (uninduced) or presence (induced) of 3 mM muristerone A. Cell cycle distribution was analysed by a¯ow cytometer after the DNA was stained with propidium iodide agents such as paclitaxel. Because p27
Kip1 could arrest the cells only in G1 phase, unless p27
Kip1 was expressed prior to exposure of the cells to paclitaxel, those cells that had already traversed through G1 phase at the time of paclitaxel treatment would not be arrested in G2 and would enter M phase, where they would become susceptible to paclitaxel-mediated apoptosis. In the experiments depicted in Figure 3a , RKO-p21 and RKO-p27 cells were subjected to a 3 h pulse exposure to paclitaxel at various concentrations, with or without subsequent induction of p21
Waf1 or p27 Kip1 during a 72 h post-paclitaxel culture period. There was a marked resistance to paclitaxel-mediated cytotoxicity when p21
Waf1 was induced in RKO-p21 cells ( Figure 3a , left panel). The IC 50 of paclitaxel was 30 nM for the noninduced cells and was more than 10 mM for the induced cells, demonstrating an over 300-fold decrease in sensitivity to paclitaxel. In contrast, there was no signi®cant dierence in the IC 50 value of paclitaxel when p27
Kip1 was induced in RKO-p27 Kip1 cells: 30 nM paclitaxel in the non-induced cells compared with 40 nM paclitaxel in the induced cells ( Figure 3a , right panel). This dierence was due to the fact that p21 Waf1 induction was associated with inhibition of paclitaxelmediated apoptosis in these cells, whereas induction of p27
Kip1 after paclitaxel treatment did not signi®cantly inhibit paclitaxel-mediated apoptosis in the RKO-p27 cells (measured by an apoptosis ELISA kit from Roche Diagnostics Corp., Indianapolis, IN, USA; data not shown).
In contrast, continuously induced expression (from 24 h before paclitaxel treatment until the MTT assay 72 h after treatment) of either p21 Waf1 or p27 Kip1 resulted in strong resistance to paclitaxel-mediated cytotoxicity on these RKO-p21 and RKO-p27 cells. (Figure 3b ). There was no signi®cant dierence between induction of p21 Waf1 and induction of p27
Kip1 in the levels of resistance conferred. Flow cytometry analysis of these induced cells after paclitaxel treatment showed cell cycle arrest patterns identical to the nonpaclitaxel-treated induced cells in Figure 2b , with accumulation in G1 phase (RKO-p27) and in G1 plus some G2 phase (RKO-p21) (data not shown). This indicates that inhibition by p21 Waf1 and p27 Kip1 prevented paclitaxel from inducing the typical G2/M arrest peak in these cells.
Dissociation of paclitaxel-mediated cytotoxicity and elevated level of p34cdc2 activity
Next we examined the eects of post-paclitaxel induction of p21
Waf1 or p27 Kip1 on paclitaxel-mediated elevation of p34cdc2 activity. p34cdc2 was immunoprecipitated with speci®c antibodies, and an in vitro kinase assay was performed using histone H1 as substrate. As expected, exposure of the non-induced RKO-p21 or RKO-p27 to 1 mM paclitaxel resulted in elevated p34cdc2 activity, which was detectable at 8 h after paclitaxel treatment. In contrast with results in the non-induced cells, induction of either p21
Kip1 after paclitaxel treatment strongly inhibited p34cdc2 kinase activity (Figure 4a,b) . These results suggest that the paclitaxel-mediated apoptosis, which continued to be observed in the induced RKO-p27 cells (Figure 3a) , was not causally related to paclitaxel- Waf1 or p27 Kip1 induction on paclitaxel-mediated cytotoxicity and apoptosis in RKO cells. RKO-p21 or RKO-p27 cells were seeded as described in Materials and methods. The treatment schedule is schematically illustrated. (a) After exposure of RKO-p21 or RKO-p27 cells to various concentrations of paclitaxel for 3 h, the cells were cultured for an additional 72 h without or with 3 mM muristerone A in culture medium. A MTT assay was performed. Values are means+ standard deviation for three independent experiments. Each experiment had triplicate wells for each treatment group. (b) Cells were preincubated with or without 3 mM muristerone A for 24 h and then was continued during and for 72 h after a 3 h exposure to various concentrations of paclitaxel. Cultures were processed as described in (a) Figure 4 Analysis of p34cdc2 kinase activity after exposure of RKO-p21 and RKO-p27 cells to paclitaxel, with or without subsequent induction of p21
Waf1 or p27 Kip1 . RKO-p21 or RKOp27 cells were exposed to 1 mM paclitaxel for 3 h. Expression of p21 Waf1 or p27 Kip1 was (+) or was not (7) subsequently induced. Control cells were not treated with paclitaxel. After the indicated post-paclitaxel intervals, cell lysates were prepared and subjected to p34cdc2 kinase assay using histone H1 as a substrate. The reaction products were separated by SDS ± PAGE and the incorporated 32 P was assayed by autoradiography Oncogene CDK inhibitors and paclitaxel sensitivity M Schmidt et al mediated p34cdc2 activation, which was blocked in these cells (Figure 4a,b) .
In the induced RKO cells, the cell cycle was arrested wholly in G1 phase by p27
Kip1 and in G1 and G2/M by p21 Waf1 (Figure 2b ), whereas the increased p34cdc2 activity and cell cycle arrest associated with paclitaxel treatment is known to occur in G2/M phase (Donaldson et al., 1994) . We therefore sought to determine in which phase RKO cells accumulated when they were treated with paclitaxel and were subsequently induced to express p21
Kip1 . After a 3 h pulse exposure of the non-induced RKOp21 or RKO-p27 cells to 1 mM paclitaxel, there was a predominant G2/M arrest in these cells during the post-paclitaxel culture period of 8 and 24 h ( Figure 5 ). In contrast, induction of p21 Waf1 or p27
Kip1 after paclitaxel treatment in these RKO cell cultures resulted in an increase of cells in G1 phase, in addition to prominent accumulation in G2/M phase. Thus, while the DNA distribution patterns were quite similar in paclitaxel-treated cells that were induced for p21
Kip1 expression post treatment ( Figure 5 ), p21
Waf1 -induced cells were protected while p27
Kip1
-induced cells were not protected from paclitaxel-mediated cytotoxicity (Figure 3a) .
In attempting to explain this apparent discrepancy, we noted that the cells in the G2/M¯ow cytometry peak could be in either G2 phase or M phase ( Figure  5 ). We hypothesized that a G2 arrest produced by induction of p21
Waf1 but not by p27
, might account for the selective protection from paclitaxel in the p21 Waf1 -induced cells by not allowing the cells to enter mitosis. Because classic one-dimensional¯ow cytometry analysis with propidium iodide DNA staining cannot distinguish the mitotic cells from G2 cells (both show 46 DNA content), we combined the¯ow cytometry analysis with a determination of mitotic indices as described in Materials and methods. There was a markedly higher number of mitotic cells in both the non-induced RKO-p21 and the non-induced RKOp27 cells 24 h after paclitaxel treatment, compared with results for untreated RKO-p21 and RKO-p27 cells (Figure 6a ). Induction of p21
Waf1 during the 24 h postpaclitaxel period resulted in a signi®cantly lower number of mitotic cells, while, in contrast, induction of p27
Kip1 during the same period produced only a very modest decrease in the number of mitotic cells ( Figure  6a ). Quantitative determination of mitotic cell indices revealed that exposure of RKO-p21 cells to paclitaxel resulted in 87.5% of the cells being in mitotic phase without induction of p21
Waf1 and 23% in mitotic phase with induction of p21 Waf1 . In contrast, exposure of RKO-p27 cells to paclitaxel resulted in 87.4% of the cells being in mitotic phase without induction of p27 Kip1 Figure 5 Cell cycle distribution analysis of paclitaxel-treated RKO cells with or without subsequent induction of p21 Waf1 or p27 Kip1 . RKO-p21 cells or RKO-p27 cells were exposed to 1 mM paclitaxel for 3 h with or without subsequent induction of p21 Waf1 or p27 Kip1 . After the indicated post-paclitaxel intervals, cells were harvested and stained with propidium iodide for cell cycle distribution analysis. Pre-G1 DNA representing apoptosis was gated out of the display patterns , which is not seen in RKO-p27 cells upon paclitaxel exposure and subsequent induction of p27 Kip1 and 74.5% in mitotic phase with p27
Kip1 induction (Figure 6b) .
We further distinguished G2 cells from cells in M phase by¯ow cytometry analysis with mithramycin staining. Cells in mitosis could be discriminated from cells in G1, S, or G2 phase by analysis of formaldehyde-®xed nuclear suspensions with mithramycin (Larsen et al., 1986) . The¯ow cytometry pattern data in Figure 6c were obtained in parallel with the experiments shown in Figure 6a ,b. Compared with results for untreated cells (upper and lower left panels), exposure of the non-induced RKO-p21 and RKO-p27 cells to paclitaxel resulted in a signi®cant accumulation of cells in mitosis (upper and lower middle panels).
Induction of p21
Waf1 resulted in a greater number of cells in both G1 and G2 phase and a lower proportion of cells in M phase (upper right panel). In contrast, induction of p27
Kip1 resulted in a higher number of cells in G1 phase cells only, no accumulation of cells at G2 phase, and persistence of a large M-phase population (lower right panel).
Taken together, these data strongly indicate that the dierence between p21 Waf1 and p27
Kip1 resulting in dierential resistance to paclitaxel treatment is attributable to the selective capacity of p21
Waf1 to block cells in G2 phase, thereby preventing entry into mitosis, where paclitaxel-mediated cell death occurs. p27 Kip1 induced paclitaxel resistance in only a fraction of the cell population, by arresting the growth of some of the RKO-p27 cells in G1 phase and thus preventing them from traversing S and G2 and entering M phase, where they would become susceptible to paclitaxel; however, the RKO-p27 cells that were already beyond the G1 checkpoint in the cell cycle could not be protected by inducing high levels of p27
Kip1 after paclitaxel treatment.
Discussion
RKO colon cancer cells express wild-type p53 and Rb (Kapoor and Lozano, 1998; van Bree et al., 1999) . RKO cells lacking functional p53 demonstrate signi®cantly enhanced sensitivity to paclitaxel compared with that of wild-type RKO cells (Frankel et al., 1997; Rakovitch et al., 1999) . Overexpression of p21 Waf1 leading to resistance of SaOs-2 human sarcoma cells to paclitaxel was also recently reported (Li et al., 1999) . In the present study, we exploited the dierential inhibitory eects of p21
Waf1 and p27 Kip1 upon G1 and G2 phases of the cell cycle to study their modulation to paclitaxel-mediated apoptosis in these cells. Our data demonstrated that the arrest of cell cycle by p21 Waf1 or p27 Kip1 had dierent eects on paclitaxel-mediated cytotoxicity in RKO cells. Induction of p21 Waf1 conferred greater resistance to paclitaxel-mediated cytotoxicity than did induction of p27 Kip1 . By combining results obtained from¯ow cytometry analysis and mitotic index analysis, we demonstrated that the additional block produced at G2 by induced p21 Waf1 prevented the cells from entering M phase and becoming susceptible to apoptosis mediated by paclitaxel. We also found that paclitaxel-mediated p34cdc2 activation was inhibited by induced expression of either p21
Waf1 or p27 Kip1 after paclitaxel treatment, although expression of p21
Waf1 resulted in far greater inhibition of paclitaxel-mediated apoptosis. The data demonstrate that paclitaxel-mediated apoptosis is not always associated with elevated levels of p34cdc2 activity and indicate that when there is a commitment to apoptosis, inhibition of p34cdc2 activity during the M phase may not hold back the apoptotic process. The strong protection of cells from paclitaxel-mediated apoptosis when p27 Kip1 was induced continuously, both before and after the paclitaxel exposure (Figure 3b) , was due to a complete G1 block in cells ± thereby preventing them from cycling through mitosis.
Our observation that ectopic expression of wild-type p27
Kip1 inhibited the activity of p34cdc2 is consistent with an earlier report showing that, in vitro, p27
Kip1 could inhibit p34cdc2 function via the N-terminal domain of p27 Kip1 (Uren et al., 1997) . However, in neither the earlier study nor our current study was p27
Kip1 induced by physiologic signals. In our study, the p34cdc2 kinase inhibition by p21
Waf1 and that by p27
Kip1 apparently had dierent eects on the physiologic activities of p34cdc2, since post-paclitaxel induction of p21 Waf1 resulted in cell arrest in G2 phase whereas postpaclitaxel induction of p27
Kip1 allowed cells to complete G2 and enter M phase, where they underwent paclitaxel-mediated apoptosis (Figures 5 and 6 ). Our data suggest that the p34cdc2 kinase activity inhibited by p21
Waf1 could be the driving force for the cells traversing from G2 to M phase, whereas in cells in which p34cdc2 kinase activity was inhibited by p27 Kip1 this was not the case. These latter cells were able to leave G2 phase and enter M phase through a possible non-p34cdc2 mechanism that remains unknown, and they were then arrested in M phase by paclitaxelmediated stabilization of microtubules ( Figure 6) .
Previous research has shown the temporal association of paclitaxel-mediated apoptosis and p34cdc2 activation, and also has demonstrated the attenuation of paclitaxel-mediated apoptosis by inhibition of p34cdc2 activity (Donaldson et al., 1994; Shen et al., 1998; Yu et al., 1998) . These studies concluded that the activity of p34cdc2 was required for paclitaxelmediated apoptosis (Yu et al., 1998) . However, because p34cdc2 plays a role at both G2 and M phases of the cell cycle, inhibition of p34cdc2 activity could aect cell cycle traversal at both phases. Thus, inhibition of cells from G2 phase to M phase could explain the results of studies showing that paclitaxel-mediated apoptosis was attenuated by inhibition of p34cdc2 by a variety of strategies, including p34cdc2 inhibitors (olomoucine or TPA), cyclin B antisense oligonucleotides, and a p34cdc2 dominant-negative expression vector (Shen et al., 1998; Yu et al., 1998) . Dissociation of paclitaxelinduced cell killing and the degree of mitotic arrest was recently reported (Rakovitch et al., 1999) . Our data suggest that the p34cdc2 activity is only required to drive cells into M phase, rendering cells susceptible to paclitaxel, whereas inhibition of p34cdc2 activity during the M phase did not inhibit the apoptotic process in the induced RKO-p27 cells. The observation showing increased p34cdc2 activity upon paclitaxel treatment maybe the result of a delayed exit of cells from M phase, due to paclitaxel-mediated disturbance of chromosome segregation at the metaphase. Similar results were observed in A431-p21 and A431-p27 clones that we produced (data not shown). Thus, the elevated level of p34cdc2 by paclitaxel treatment is more likely to be a consequence of paclitaxel treatment than the mechanism by which paclitaxel activates and induces apoptosis.
Materials and methods
Cell culture
RKO human colon adenocarcinoma master cell clone expressing pIND-regulatory vector pVgRXR was provided by J Parant and G Lozano (The University of Texas MD Anderson Cancer Center, Houston, TX, USA). The cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin G, 100 mg/ml streptomycin, 0.25 mg/ml amphotericin B and 200 mg/ml Zeocin.
Construction of p21
Waf1 and p27 Kip1 pIND vectors Kip1 -transfected clones were kept in double selection culture medium containing 200 mg/ml Zeocin and 500 mg/ml neomycin (G418). The expression of p21 Waf1 or p27 Kip1 was induced by 3 mM muristerone A for 24 h and examined by Western blot analysis with speci®c antibodies. Clones with high expression levels of p21
Waf1 or p27 Kip1 upon their induction were selected for further study.
Cell proliferation assay
RKO cells were seeded onto 6-well culture plates at a density of 2610 4 cells/well in growing medium supplemented with 10% FBS and were cultured for 5 days in triplicate in the presence or absence of 3 mM muristerone A. Cells were counted with a Coulter counter after harvesting by trypsinization.
Flow cytometry analysis
Cell cycle distribution analysis with propidium iodide was previously described (Fan et al., 1995) . For analysis with mithramycin staining, an aliquot of 2610 6 cells was incubated with 2 ml of 0.1% nonidet P-40 in PBS for 5 min, followed by ®xation with the addition of 0.7 ml of 4% formaldehyde in PBS and gentle shaking of the cells at 48C for 15 min. DNA was stained with 20 mg/ml mithramycin A (Sigma, St Louis, MO, USA). The green¯uorescence of mithramycin A was analysed with a¯ow cytometer under a 515+20 nm band pass ®lter with an excitation wavelength of 488 nm.
Immunoblot analysis
Cells were lysed as previously described (Fan et al., 1995) . Speci®c signals were visualized by the ECL chemoluminescence detection kit (Amersham, Arlington Heights, IL, USA).
CDK kinase assays
The kinase assay with Rb or histone H1 as substrates was performed as previously described (Fan et al., 1995; Wu et al., 1996) .
Paclitaxel cytotoxicity assay (MTT assay)
Cells were seeded onto 24-well culture plates. Cell viability was assayed by adding 50 ml of 10 mg/ml MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) (Sigma) into 0.5 ml of culture medium and incubating the cells for 3 h at a 378C in a CO 2 incubator, followed by cell lysis with 500 ml of lysis buer containing 20% SDS in dimethyl formamide/H 2 O, pH 4.7, at 378C for more than 6 h. Cell viability was then determined by measuring the optical absorbance of cell lysate at a wavelength of 595 nm and normalizing the value with the corresponding control (paclitaxel-untreated cells).
Determination of mitotic index
Upon completion of the desired treatment, cells were harvested by trypsinization. An aliquot (5610 3 cells) was spun on glass slides using a Cytospin and subsequently ®xed and stained with the Hema-3 kit (Biochemical Sciences, Inc., Swedesboro, NJ, USA) and examined microscopically. Twohundred cells were counted from ®ve dierent areas, for a total of 1000 cells. Cells in mitotic phase were individually scored, and the numbers were expressed as the percentage of the total cell number counted. Representative areas for each treatment condition were photographed.
Abbreviations CDK, cyclin-dependent kinase; CDC2, cell division control-2
